Literature DB >> 2450839

Eosinophil-activating factor (EAF) production by a human cell line (ESH 98) stimulated with tumour necrosis factor.

K J Thorne1, B A Richardson, A E Butterworth, M Stanley.   

Abstract

A new cell line has been produced by fusing human cervical keratinocytes with HeLa cells. This cell line secretes eosinophil-activating activity upon stimulation with tumour necrosis factor (TNF). About one-third of the eosinophil-activating activity co-purifies with eosinophil-activating factor (EAF) from mononuclear cell supernatants. The purification procedure indicates that it resembles EAF in molecular weight and acidity. It also resembles EAF in its effect on eosinophils. Not only does it enhance the cytotoxic activity of eosinophils to antibody-coated schistosomula of Schistosoma mansoni, but it also increases the oxidative activity of eosinophils, as measured by reduction of nitroblue tetrazolium, and changes the morphology of eosinophils, affecting the distribution of F-actin in the cell.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2450839      PMCID: PMC1454751     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  21 in total

1.  Partial purification and biological properties of an eosinophil-activating factor.

Authors:  K J Thorne; B A Richardson; M C Veith; P C Tai; C J Spry; A E Butterworth
Journal:  Eur J Immunol       Date:  1985-11       Impact factor: 5.532

2.  Eosinophil differentiation factor also has B-cell growth factor activity: proposed name interleukin 4.

Authors:  C J Sanderson; A O'Garra; D J Warren; G G Klaus
Journal:  Proc Natl Acad Sci U S A       Date:  1986-01       Impact factor: 11.205

3.  A new method for the purification of human eosinophils and neutrophils, and a comparison of the ability of these cells to damage schistosomula of Schistosoma mansoni.

Authors:  M A Vadas; J R David; A Butterworth; N T Pisani; T A Siongok
Journal:  J Immunol       Date:  1979-04       Impact factor: 5.422

4.  An endotoxin-induced serum factor that causes necrosis of tumors.

Authors:  E A Carswell; L J Old; R L Kassel; S Green; N Fiore; B Williamson
Journal:  Proc Natl Acad Sci U S A       Date:  1975-09       Impact factor: 11.205

5.  Studies on the enhancement of human eosinophil function by mononuclear cell products in vitro.

Authors:  M Veith; D W Taylor; K Thorne; B A Richardson; A E Butterworth
Journal:  Clin Exp Immunol       Date:  1984-12       Impact factor: 4.330

6.  Growth requirements of human cervical epithelial cells in culture.

Authors:  M A Stanley; E K Parkinson
Journal:  Int J Cancer       Date:  1979-10-15       Impact factor: 7.396

7.  Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells.

Authors:  P Libby; J M Ordovas; K R Auger; A H Robbins; L K Birinyi; C A Dinarello
Journal:  Am J Pathol       Date:  1986-08       Impact factor: 4.307

8.  Characteristics of colony-stimulating factor production by murine T-lymphocyte clones.

Authors:  A Kelso; D Metcalf
Journal:  Exp Hematol       Date:  1985-01       Impact factor: 3.084

9.  Tumor necrosis factor enhances eosinophil toxicity to Schistosoma mansoni larvae.

Authors:  D S Silberstein; J R David
Journal:  Proc Natl Acad Sci U S A       Date:  1986-02       Impact factor: 11.205

10.  Enhancement of human eosinophil-mediated killing of Schistosoma mansoni larvae by mononuclear cell products in vitro.

Authors:  M C Veith; A E Butterworth
Journal:  J Exp Med       Date:  1983-06-01       Impact factor: 14.307

View more
  2 in total

1.  The effects of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 on the secretory capacity of human blood eosinophils.

Authors:  P C Tai; C J Spry
Journal:  Clin Exp Immunol       Date:  1990-06       Impact factor: 4.330

2.  Immunological crossreactivity between a cloned antigen of Onchocerca volvulus and a component of the retinal pigment epithelium.

Authors:  G Braun; N M McKechnie; V Connor; C E Gilbert; F Engelbrecht; J A Whitworth; D W Taylor
Journal:  J Exp Med       Date:  1991-07-01       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.